These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a Spratt DE; Alshalalfa M; Fishbane N; Weiner AB; Mehra R; Mahal BA; Lehrer J; Liu Y; Zhao SG; Speers C; Morgan TM; Dicker AP; Freedland SJ; Karnes RJ; Weinmann S; Davicioni E; Ross AE; Den RB; Nguyen PL; Feng FY; Lotan TL; Chinnaiyan AM; Schaeffer EM Clin Cancer Res; 2019 Nov; 25(22):6721-6730. PubMed ID: 31515456 [TBL] [Abstract][Full Text] [Related]
7. ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. Rotinen M; You S; Yang J; Coetzee SG; Reis-Sobreiro M; Huang WC; Huang F; Pan X; Yáñez A; Hazelett DJ; Chu CY; Steadman K; Morrissey CM; Nelson PS; Corey E; Chung LWK; Freedland SJ; Di Vizio D; Garraway IP; Murali R; Knudsen BS; Freeman MR Nat Med; 2018 Dec; 24(12):1887-1898. PubMed ID: 30478421 [TBL] [Abstract][Full Text] [Related]
8. The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer. Lundberg A; Zhang M; Aggarwal R; Li H; Zhang L; Foye A; Sjöström M; Chou J; Chang K; Moreno-Rodriguez T; Shrestha R; Baskin A; Zhu X; Weinstein AS; Younger N; Alumkal JJ; Beer TM; Chi KN; Evans CP; Gleave M; Lara PN; Reiter RE; Rettig MB; Witte ON; Wyatt AW; Feng FY; Small EJ; Quigley DA Cancer Res; 2023 Aug; 83(16):2763-2774. PubMed ID: 37289025 [TBL] [Abstract][Full Text] [Related]
9. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. Sharp A; Welti JC; Lambros MBK; Dolling D; Rodrigues DN; Pope L; Aversa C; Figueiredo I; Fraser J; Ahmad Z; Lu C; Rescigno P; Kolinsky M; Bertan C; Seed G; Riisnaes R; Miranda S; Crespo M; Pereira R; Ferreira A; Fowler G; Ebbs B; Flohr P; Neeb A; Bianchini D; Petremolo A; Sumanasuriya S; Paschalis A; Mateo J; Tunariu N; Yuan W; Carreira S; Plymate SR; Luo J; de Bono JS Eur Urol; 2019 Nov; 76(5):676-685. PubMed ID: 31036442 [TBL] [Abstract][Full Text] [Related]
10. Clinical and molecular features of treatment-related neuroendocrine prostate cancer. Akamatsu S; Inoue T; Ogawa O; Gleave ME Int J Urol; 2018 Apr; 25(4):345-351. PubMed ID: 29396873 [TBL] [Abstract][Full Text] [Related]
11. RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer. Nava Rodrigues D; Casiraghi N; Romanel A; Crespo M; Miranda S; Rescigno P; Figueiredo I; Riisnaes R; Carreira S; Sumanasuriya S; Gasperini P; Sharp A; Mateo J; Makay A; McNair C; Schiewer M; Knudsen K; Boysen G; Demichelis F; de Bono JS Clin Cancer Res; 2019 Jan; 25(2):687-697. PubMed ID: 30257982 [TBL] [Abstract][Full Text] [Related]
12. Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription. Jia L; Wu D; Wang Y; You W; Wang Z; Xiao L; Cai G; Xu Z; Zou C; Wang F; Teoh JY; Ng CF; Yu S; Chan FL Oncogene; 2018 Jun; 37(25):3340-3355. PubMed ID: 29555975 [TBL] [Abstract][Full Text] [Related]
13. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate. Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429 [TBL] [Abstract][Full Text] [Related]
14. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. Labrecque MP; Coleman IM; Brown LG; True LD; Kollath L; Lakely B; Nguyen HM; Yang YC; da Costa RMG; Kaipainen A; Coleman R; Higano CS; Yu EY; Cheng HH; Mostaghel EA; Montgomery B; Schweizer MT; Hsieh AC; Lin DW; Corey E; Nelson PS; Morrissey C J Clin Invest; 2019 Jul; 129(10):4492-4505. PubMed ID: 31361600 [TBL] [Abstract][Full Text] [Related]
15. Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer. Saylor PJ; Lee RJ; Arora KS; Deshpande V; Hu R; Olivier K; Meneely E; Rivera MN; Ting DT; Wu CL; Miyamoto DT Clin Cancer Res; 2017 Jan; 23(2):363-369. PubMed ID: 27440270 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive Profiling of the Androgen Receptor in Liquid Biopsies from Castration-resistant Prostate Cancer Reveals Novel Intra-AR Structural Variation and Splice Variant Expression Patterns. De Laere B; van Dam PJ; Whitington T; Mayrhofer M; Diaz EH; Van den Eynden G; Vandebroek J; Del-Favero J; Van Laere S; Dirix L; Grönberg H; Lindberg J Eur Urol; 2017 Aug; 72(2):192-200. PubMed ID: 28104311 [TBL] [Abstract][Full Text] [Related]
17. Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer. Buonerba C; Di Lorenzo G; Sonpavde G Expert Rev Mol Diagn; 2016 Oct; 16(10):1113-1120. PubMed ID: 27665838 [TBL] [Abstract][Full Text] [Related]
18. Telomere lengths differ significantly between small-cell neuroendocrine prostate carcinoma and adenocarcinoma of the prostate. Heaphy CM; Haffner MC; Graham MK; Lim D; Davis C; Corey E; Epstein JI; Eisenberger MA; Wang H; De Marzo AM; Meeker AK; Lotan TL Hum Pathol; 2020 Jul; 101():70-79. PubMed ID: 32389660 [TBL] [Abstract][Full Text] [Related]